Senate committee rejects bill to require labeling of blood donations by COVID‑19 vaccine status

The Senate Health and Welfare Committee declined to advance House Bill 131 after a lengthy hearing in which blood collection organizations, hospital officials and transfusion‑medicine physicians uniformly warned the proposal could not be implemented under existing federal rules and could jeopardize Idaho’s blood supply.

Representative Bruce, the bill’s sponsor, said HB 131 was intended to protect informed consent and allow non‑emergency patients to request blood that did not come from donors who said they had received an mRNA COVID‑19 vaccine. “I’m not challenging the safety of the vaccination… I’m just saying that people have the right to choose. It’s an informed consent decision,” Bruce told the committee.

Witnesses representing Vitalant and the American Red Cross, plus hospital and blood‑bank physicians, opposed the bill. Michael Martinez, regional director for Vitalant, said the blood‑safety system is regulated as a pharmaceutical supply and does not have a test that distinguishes vaccine‑induced antibodies from antibodies produced by infection: “Labeling blood products based on the self disclosed and therefore fundamentally unreliable information for no medical or scientific reason is impractical and it's unprecedented,” Martinez said.

Nicole Erwin, CEO of the American Red Cross of Idaho, told senators the Red Cross operates multiple centers across the state and that the organization cannot label units for vaccine status because there is no laboratory test and the Food and Drug Administration (FDA) and accrediting bodies require labels to be supported by verifiable data. “If we can't verify it, we can't label it,” Erwin said.

Hospital and blood‑bank witnesses also warned that adding the question and the requested labels would increase complexity, risk reducing the donor pool and could require costly new infrastructure to manage separately labeled inventories. Toni Lawson, vice president of the Idaho Hospital Association, asked the committee to hold the bill, saying Idaho already experiences shortages several times per year and that further constraints could worsen availability.

Several individuals testified in favor of the bill, including a patient who described difficulties obtaining physician‑directed donations and a constituent who said donor labeling would protect personal choice. Representative Bruce argued the statute could be written to require only a disclosure and a label if the donor self‑reported status, and he cited portions of federal regulations in committee remarks while asserting states may add local requirements so long as safety is preserved.

Senators expressed divided views in debate. Supporters described the bill as a matter of consumer choice; opponents, including multiple senators and the medical witnesses, said the proposal would be infeasible under current FDA rules, could mislead patients if labeling relied on unverified donor statements and risked reducing available blood. Senator Lenny said she could not support the bill because donor self‑reporting cannot be relied on; Senator Shippey and others called for more study or alternative approaches to let patients request directed or reserved donations under current medical protocols.

Senator Ziederfeld moved to send HB 131 to the floor with a due pass recommendation; the motion was seconded. After discussion the committee voted; the motion failed.

Why it matters: HB 131 drew high‑stake testimony from the organizations that collect and supply blood in Idaho and from physicians who manage hospital blood inventories. Opponents argued the measure would be impossible to implement in the current regulatory framework and could reduce access to life‑saving blood products. The committee’s decision leaves the state’s current practice in place while signaling stakeholders’ need for further technical study or federal guidance before any policy change.